DAISYPhase 2 · started 2024 · withdrawn BIIB131 in ischemic stroke · n=0
Reason given: Sponsor decision
CYPRESSPhase 2 · started 2023 · terminated RTA 901 in diabetic peripheral neuropathic pain · n=209
Reason given: Sponsor decision to close study early; not due to safety concerns.
SURGE-1Phase 3 · started 2023 · withdrawn BIIB074 in trigeminal neuralgia · n=0
Reason given: Sponsor Decision
SURGE-2Phase 3 · started 2023 · withdrawn BIIB074 in trigeminal neuralgia · n=0
Reason given: Sponsor Decision
BIIB122 in parkinson disease · n=7
Reason given: Sponsor Decision
ENVISIONPhase 3 · started 2022 · terminated Aducanumab in alzheimer's disease · n=1027
Reason given: Sponsor's Decision
Natalizumab in multiple sclerosis, relapsing-remitting · n=21
Reason given: Due to sponsor decision, not for efficacy or safety reasons.
Placebo in relapsing multiple sclerosis · n=0
Reason given: Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns.
ALSpirePhase 1/2 · started 2020 · terminated BIIB105 in amyotrophic lateral sclerosis · n=99
Reason given: Sponsor's decision
Aducanumab in alzheimer's disease · n=1696
Reason given: Sponsor's Decision
SAGE-217 in major depressive disorder · n=53
Reason given: Internal company decision
FALCONPhase 3 · started 2019 · terminated Bardoxolone methyl oral capsule in autosomal dominant polycystic kidney · n=667
Reason given: Discontinuation of all bardoxolone chronic kidney disease programs
Dimethyl Fumarate in multiple sclerosis, relapsing-remitting · n=11
Reason given: Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.
EAGLEPhase 3 · started 2019 · terminated Bardoxolone methyl in chronic kidney diseases · n=270
Reason given: Discontinuation of all bardoxolone chronic kidney disease programs
SAGE-217 in major depressive disorder · n=87
Reason given: internal company decision
EVOLVEPhase 2 · started 2018 · terminated Aducanumab in cognitive dysfunction · n=52
Reason given: Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
SPIRITPhase 2 · started 2018 · terminated BG00011 in idiopathic pulmonary fibrosis · n=109
Reason given: Study was stopped because of safety concerns.
BIIB074 in small fiber neuropathy · n=265
Reason given: Sponsor decision to close study early; not due to safety concerns
TANGOPhase 2 · started 2018 · terminated BIIB092 in alzheimer's disease · n=654
Reason given: The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.
SPARKPhase 2 · started 2018 · terminated Placebo in parkinson's disease · n=357
Reason given: SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.
AFFINITYPhase 2 · started 2017 · terminated BIIB033 (opicinumab) in multiple sclerosis · n=263
Reason given: The top-line results from the Part 1 did not meet the pre-specified primary endpoint nor the key secondary endpoints. The decision to discontinue study 215MS202 Part 2 was not based on safety concerns.
PASSPORTPhase 2 · started 2017 · terminated BIIB092 in supranuclear palsy, progressive · n=490
Reason given: 251PP301(PASSPORT) primary endpoint was not met;Biogen decision to close the study early. There were no safety concerns with the PASSPORT study.
SUSTAINPhase 3 · started 2017 · terminated Daclizumab in relapsing-remitting multiple sclerosis (rrms) · n=41
Reason given: Study terminated in line with Biogen decision to withdraw Zinbryta from the market and not to pursue further studies of daclizumab in MS.
RANGERPhase 3 · started 2017 · terminated Bardoxolone methyl in pulmonary hypertension · n=261
Reason given: The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
BIIB074 in neuropathic pain from lumbosacral radiculopathy · n=302
Reason given: The parent study did not meet its primary or secondary efficacy endpoints and therefore Sponsor decision to discontinue development in this indication.
Placebo capsules in connective tissue disease-associated pulmonary arterial hypertension · n=202
Reason given: Exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health
PF-04958242 in cognitive impairment associated with schizophrenia (cias) · n=35
Reason given: Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not due to any safety concern or change in benefit:risk assessment.
dimethyl fumarate in relapsing-remitting multiple sclerosis · n=0
Reason given: Feasibility
EMERGEPhase 3 · started 2015 · terminated Aducanumab (BIIB037) in alzheimer's disease · n=1643
Reason given: Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
EMBRACEPhase 2 · started 2015 · terminated Nusinersen in spinal muscular atrophy · n=21
Reason given: The study was terminated early to roll over participants to open label extension study NCT02594124.
ENGAGEPhase 3 · started 2015 · terminated Aducanumab (BIIB037) in alzheimer's disease · n=1653
Reason given: Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
INSPIREPhase 3 · started 2015 · terminated dimethyl fumarate in multiple sclerosis, secondary progressive · n=58
Reason given: Sponsor Decision
dimethyl fumarate in multiple sclerosis · n=62
Reason given: Sponsor decision
SIMPLIFYPhase 2 · started 2014 · terminated natalizumab in relapsing multiple sclerosis · n=2
Reason given: Sponsor's decision.
ENDEARPhase 3 · started 2014 · terminated nusinersen in spinal muscular atrophy · n=122
Reason given: After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study
BIIB023 in lupus nephritis · n=87
Reason given: Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate sufficient efficacy to warrant continuation of the study
EXTENDPhase 3 · started 2013 · terminated BIIB019 (Daclizumab) in relapsing-remitting multiple sclerosis · n=1501
Reason given: Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.
Bardoxolone Methyl in renal insufficiency, chronic · n=0
Reason given: IDMC recommendation for safety concerns
EMBRACEPhase 2 · started 2012 · withdrawn BIIB057 in rheumatoid arthritis · n=0
No reason recorded in the registry.
Bardoxolone Methyl 20 mg in end-stage renal disease · n=0
Reason given: IDMC recommendation for safety concerns
ATLASPhase 2 · started 2012 · terminated BIIB023 in lupus nephritis · n=276
Reason given: Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.
natalizumab in secondary progressive multiple sclerosis · n=889
Reason given: The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
BEACONPhase 3 · started 2011 · terminated Placebo in renal insufficiency, chronic · n=2185
Reason given: IDMC recommendation for safety concerns
Placebo in secondary progressive multiple sclerosis · n=0
No reason recorded in the registry.
SURPASSPhase 3 · started 2010 · terminated BG00002 (natalizumab) in relapsing remitting multiple sclerosis · n=84
Reason given: Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.
POSEIDONPhase 2 · started 2009 · terminated Tonapofylline in renal insufficiency · n=34
Reason given: Company Decision
mefloquine in progressive multifocal leukoencephalopathy · n=37
Reason given: Primary endpoint not achieved
BG9418 (interferon beta 1-a) in multiple sclerosis · n=3
Reason given: Terminated early by Sponsor for business reasons unrelated to safety.
BG00002 (natalizumab) in multiple myeloma · n=6
Reason given: Sponsor decision due to low enrollment and not safety concerns.
Lumiliximab + FCR in chronic lymphocytic leukemia · n=40
No reason recorded in the registry.
galiximab in combination with rituximab in lymphoma, non-hodgkin's · n=16
Reason given: Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
Baminercept alfa (BG9924) in rheumatoid arthritis · n=339
Reason given: Analysis of data from 104RA202 failed to meet primary endpoint
berubicin hydrochloride (RTA 744) in brain metastases · n=14
Reason given: Business Decision
BG9924 in rheumatoid arthritis · n=72
Reason given: Analysis of data from 104RA203 failed to meet primary endpoint.
RTA 402 in liver disease · n=16
Reason given: Enrollment discontinued after second cohort completed.
BG9924 in rheumatoid arthritis · n=115
Reason given: Interim analysis of data failed to meet primary endpoint.
LUCIDPhase 2 · started 2006 · terminated FCR + Lumiliximab in chronic lymphocytic leukemia · n=627
No reason recorded in the registry.
Galiximab in combination with rituximab in lymphoma, non-hodgkin's · n=340
Reason given: Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
IDEC-C2B8 (rituximab) in rheumatoid arthritis · n=54
Reason given: Sponsor decided to end long term extension phase for business reasons unrelated to safety.
STRATAPhase 3 · started 2006 · terminated Natalizumab in relapsing-remitting multiple sclerosis · n=1094
No reason recorded in the registry.
Unconjugated IDEC-159 in colorectal cancer · n=30
No reason recorded in the registry.
natalizumab in rheumatoid arthritis
Reason given: The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
natalizumab in rheumatoid arthritis · n=299
Reason given: The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
Zevalin (ibritumomab tiuxetan) in non-hodgkin's lymphoma · n=400
No reason recorded in the registry.
RTA 402 Dose1 in malignant melanoma · n=0
No reason recorded in the registry.
active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. in parkinson's disease · n=0
No reason recorded in the registry.